Aryl ureas with angiogenesis inhibiting activity
US7838541B2 · kind B2 · utility
52Cited by
204References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2003 |
| Grant date | Nov 23, 2010 |
| Priority date | — |
| Expiry date | Feb 11, 2023 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.